|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KANK1 |
Gene summary for KANK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KANK1 | Gene ID | 23189 |
| Gene name | KN motif and ankyrin repeat domains 1 | |
| Gene Alias | ANKRD15 | |
| Cytomap | 9p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q14678 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23189 | KANK1 | CCI_2 | Human | Cervix | CC | 8.90e-11 | 1.13e+00 | 0.5249 |
| 23189 | KANK1 | CCI_3 | Human | Cervix | CC | 2.38e-25 | 1.33e+00 | 0.516 |
| 23189 | KANK1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.57e-03 | 3.92e-01 | -0.1954 |
| 23189 | KANK1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.25e-03 | 5.77e-01 | -0.059 |
| 23189 | KANK1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.34e-05 | 5.61e-01 | 0.0446 |
| 23189 | KANK1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 3.01e-04 | 6.80e-01 | 0.0131 |
| 23189 | KANK1 | HTA11_7469_2000001011 | Human | Colorectum | AD | 6.36e-03 | -8.09e-01 | -0.0124 |
| 23189 | KANK1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.60e-32 | 1.49e+00 | 0.3487 |
| 23189 | KANK1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.50e-22 | 1.27e+00 | 0.281 |
| 23189 | KANK1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.62e-07 | 7.93e-01 | 0.3859 |
| 23189 | KANK1 | A001-C-207 | Human | Colorectum | FAP | 7.96e-04 | 1.90e-01 | 0.1278 |
| 23189 | KANK1 | A015-C-203 | Human | Colorectum | FAP | 1.76e-13 | -1.94e-01 | -0.1294 |
| 23189 | KANK1 | A002-C-201 | Human | Colorectum | FAP | 6.82e-03 | -1.92e-01 | 0.0324 |
| 23189 | KANK1 | A001-C-108 | Human | Colorectum | FAP | 2.04e-05 | -2.42e-03 | -0.0272 |
| 23189 | KANK1 | A002-C-205 | Human | Colorectum | FAP | 8.13e-14 | -3.16e-01 | -0.1236 |
| 23189 | KANK1 | A001-C-104 | Human | Colorectum | FAP | 4.15e-04 | 6.19e-02 | 0.0184 |
| 23189 | KANK1 | A015-C-006 | Human | Colorectum | FAP | 3.77e-12 | -3.73e-01 | -0.0994 |
| 23189 | KANK1 | A015-C-106 | Human | Colorectum | FAP | 6.23e-05 | 3.59e-02 | -0.0511 |
| 23189 | KANK1 | A002-C-114 | Human | Colorectum | FAP | 4.40e-15 | -5.33e-01 | -0.1561 |
| 23189 | KANK1 | A015-C-104 | Human | Colorectum | FAP | 1.74e-20 | -2.60e-01 | -0.1899 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003444616 | Prostate | BPH | substrate adhesion-dependent cell spreading | 43/3107 | 108/18723 | 7.20e-09 | 2.50e-07 | 43 |
| GO:00301119 | Prostate | BPH | regulation of Wnt signaling pathway | 95/3107 | 328/18723 | 1.23e-08 | 3.99e-07 | 95 |
| GO:003004116 | Prostate | BPH | actin filament polymerization | 63/3107 | 191/18723 | 1.94e-08 | 5.98e-07 | 63 |
| GO:00109759 | Prostate | BPH | regulation of neuron projection development | 118/3107 | 445/18723 | 5.85e-08 | 1.57e-06 | 118 |
| GO:190002416 | Prostate | BPH | regulation of substrate adhesion-dependent cell spreading | 27/3107 | 57/18723 | 6.30e-08 | 1.67e-06 | 27 |
| GO:000806415 | Prostate | BPH | regulation of actin polymerization or depolymerization | 61/3107 | 188/18723 | 6.37e-08 | 1.68e-06 | 61 |
| GO:003083316 | Prostate | BPH | regulation of actin filament polymerization | 57/3107 | 172/18723 | 7.52e-08 | 1.92e-06 | 57 |
| GO:003083210 | Prostate | BPH | regulation of actin filament length | 61/3107 | 189/18723 | 7.89e-08 | 2.00e-06 | 61 |
| GO:00608289 | Prostate | BPH | regulation of canonical Wnt signaling pathway | 75/3107 | 253/18723 | 1.47e-07 | 3.43e-06 | 75 |
| GO:190290410 | Prostate | BPH | negative regulation of supramolecular fiber organization | 55/3107 | 167/18723 | 1.60e-07 | 3.63e-06 | 55 |
| GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
| GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
| GO:003001010 | Prostate | BPH | establishment of cell polarity | 48/3107 | 143/18723 | 5.10e-07 | 1.03e-05 | 48 |
| GO:00600709 | Prostate | BPH | canonical Wnt signaling pathway | 84/3107 | 303/18723 | 6.54e-07 | 1.27e-05 | 84 |
| GO:003286910 | Prostate | BPH | cellular response to insulin stimulus | 61/3107 | 203/18723 | 1.26e-06 | 2.20e-05 | 61 |
| GO:00071628 | Prostate | BPH | negative regulation of cell adhesion | 82/3107 | 303/18723 | 2.51e-06 | 4.04e-05 | 82 |
| GO:006104110 | Prostate | BPH | regulation of wound healing | 44/3107 | 134/18723 | 2.91e-06 | 4.61e-05 | 44 |
| GO:003286810 | Prostate | BPH | response to insulin | 73/3107 | 264/18723 | 3.80e-06 | 5.83e-05 | 73 |
| GO:190303416 | Prostate | BPH | regulation of response to wounding | 51/3107 | 167/18723 | 5.43e-06 | 8.01e-05 | 51 |
| GO:19027439 | Prostate | BPH | regulation of lamellipodium organization | 23/3107 | 54/18723 | 5.78e-06 | 8.47e-05 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KANK1 | SNV | Missense_Mutation | rs761714605 | c.2255N>T | p.Ser752Leu | p.S752L | Q14678 | protein_coding | deleterious(0.01) | benign(0.219) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| KANK1 | SNV | Missense_Mutation | rs775231755 | c.3806N>T | p.Thr1269Met | p.T1269M | Q14678 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
| KANK1 | SNV | Missense_Mutation | novel | c.2756N>T | p.Ser919Ile | p.S919I | Q14678 | protein_coding | tolerated(0.2) | benign(0.08) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KANK1 | SNV | Missense_Mutation | c.2482N>C | p.Glu828Gln | p.E828Q | Q14678 | protein_coding | tolerated(0.08) | probably_damaging(0.981) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| KANK1 | SNV | Missense_Mutation | novel | c.3775N>A | p.Asp1259Asn | p.D1259N | Q14678 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KANK1 | SNV | Missense_Mutation | novel | c.2071N>T | p.Leu691Phe | p.L691F | Q14678 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| KANK1 | SNV | Missense_Mutation | novel | c.847N>G | p.Thr283Ala | p.T283A | Q14678 | protein_coding | tolerated(0.09) | probably_damaging(0.917) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KANK1 | SNV | Missense_Mutation | c.3232N>A | p.Glu1078Lys | p.E1078K | Q14678 | protein_coding | deleterious(0.04) | benign(0.147) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| KANK1 | SNV | Missense_Mutation | novel | c.908C>T | p.Ser303Leu | p.S303L | Q14678 | protein_coding | deleterious(0.03) | benign(0.005) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| KANK1 | SNV | Missense_Mutation | novel | c.1960G>A | p.Ala654Thr | p.A654T | Q14678 | protein_coding | tolerated(0.62) | benign(0) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |